QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN's therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim's targeted therapy GILOTRIF® (afatinib) for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-resistant epidermal growth factor receptor (EGFR) mutations. The approval extends the labeling claim to include detection of EGFR mutations L681Q, G719X and S768I to aid the identification of NSCLC patients for whom GILOTRIF® (afatinib) is indicated. The therascreen® EGFR RGQ PCR Kit now detects the most comprehensive panel of EGFR mutations in which the safety and efficacy of GILOTRIF® (afatinib) have been established.
Click here for the full press release.
https://corporate.qiagen.com/newsroom/press-releases/2017/20180118_therascreen_EGFR?sc_lang=en
Contacts:
QIAGEN
Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711
Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826
SOURCE QIAGEN N.V.
